VivoSeq
Respiratory

Emphysema

29

Pipeline Programs↗

4

Active Trials↗

16

Companies Involved↗

Emphysema is an emerging landscape with 29 programs across 16 companies. The most active players are Sanofi, Roche, Mario Negri Institute for Pharmacological Research. 8 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

27/100

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 2Roche logo

Roche

1 program

Phase 2Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 2Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

25 of 27 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody14%Cell therapy14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

30

clinical trials

Completed18 · 60%
Unknown status4 · 13%
Recruiting2 · 7%
Withdrawn2 · 7%
Terminated2 · 7%
Active, not recruiting2 · 7%

Clinical Trials

Trial Activity

30 trials

Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema
Recruiting·MMansoura University Hospital·N/A·NCT06629558·30 enrolled
Bronchoscopic Lung Volume Reduction With Endobronchial Silicone Valve for Patients With Emphysema: a Randomised Controlled Trial
Recruiting·CChina-Japan Friendship Hospital·Preclinical·NCT07097896·147 enrolled
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT05382208·133 enrolled
Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
Active, not recruiting·—·Phase 4·NCT02682147·17 enrolled
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Completed·Grifols Therapeutics LLC logoGrifols Therapeutics LLC·Phase 2·NCT00263887·77 enrolled
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
Completed·AAeris Therapeutics·Phase 1·NCT00347659·6 enrolled
Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema
Completed·LLeiden University Medical Center·Phase 1·NCT01306513·10 enrolled
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000621
Efficacy Study of the Effect of Budesonide on Emphysema
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT00232674·240 enrolled
Losartan Effects on Emphysema Progression
Completed·JJHSPH Center for Clinical Trials·Phase 4·NCT02696564·220 enrolled
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Completed·CSL Behring logoCSL Behring·Phase 4·NCT00670007·140 enrolled
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
Completed·Roche logoRoche·Phase 2·NCT00413205·491 enrolled
Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT03244059·17 enrolled
US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation
Completed·AAeris Therapeutics·Phase 1·NCT00085852·6 enrolled
Prostaglandin Inhibition for Emphysema
Completed·UUniversity of Nebraska·Phase 2·NCT02006576·118 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)